<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01048307</url>
  </required_header>
  <id_info>
    <org_study_id>OPM-I-H-0902</org_study_id>
    <nct_id>NCT01048307</nct_id>
  </id_info>
  <brief_title>Effect of Prontosan Wound Irrigation Solution on Venous Ulcers</brief_title>
  <official_title>Randomised, Controlled, Clinical Trial on the Safety and Efficacy of Prontosan Wound Irrigation Solution Compared to Standard Therapy in the Treatment of Hard-to-Heal Venous Leg Ulcers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Calvary Hospital, Bronx, NY</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>B. Braun Medical SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Calvary Hospital, Bronx, NY</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:&#xD;
&#xD;
      To evaluate the efficacy and safety of Prontosan® Wound Irrigation Solution in the treatment&#xD;
      of hard-to-heal venous leg ulcers compared to wound irrigation with saline solution&#xD;
&#xD;
      Methodology:&#xD;
&#xD;
      Randomised, controlled multi-centre, prospective clinical trial&#xD;
&#xD;
      Planned number of subjects:&#xD;
&#xD;
      20 patients in experimental group (Prontosan® Wound Irrigation Solution) 8 patients in&#xD;
      control group (wound irrigation with saline)&#xD;
&#xD;
      Products under investigation:&#xD;
&#xD;
      Prontosan® Wound Irrigation Solution&#xD;
&#xD;
      Study Duration:&#xD;
&#xD;
      3-4 weeks&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigational product, dose and administration:&#xD;
&#xD;
      Prontosan® Wound Irrigation Solution (experimental group) and saline solution (control group)&#xD;
      will be applied at inclusion and reapplied after dressing changes.&#xD;
&#xD;
      The treatment scheme is as follows:&#xD;
&#xD;
        1. Prontosan® Wound Irrigation Solution (experimental group):&#xD;
&#xD;
             -  cleansing the wound bed at dressing change with Prontosan® Wound Irrigation&#xD;
                Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be&#xD;
                placed on the immediate wound in the form of a moist compress and removed after&#xD;
                approximately 15 minutes;&#xD;
&#xD;
             -  placing the primary dressing (Profore® WCL): the dressing will be impregnated with&#xD;
                Prontosan® Wound Irrigation Solution;&#xD;
&#xD;
             -  fixing the dressing to the wound using multilayered elastic compression bandaging&#xD;
                (Profore® bandaging system).&#xD;
&#xD;
        2. Saline (control group):&#xD;
&#xD;
             -  cleansing the wound bed at dressing change with saline; a sterile gauze dressing&#xD;
                impregnated with the saline will be placed on the wound in the form of a moist&#xD;
                compress and removed after approx.15 minutes;&#xD;
&#xD;
             -  placing the primary dressing (Profore® WCL): the dressing will be impregnated with&#xD;
                saline;&#xD;
&#xD;
             -  fixing the dressing to the wound using multilayered elastic compression bandaging&#xD;
                (Profore® bandaging system).&#xD;
&#xD;
      Dressings will be changed and the treatment procedure will be repeated in the clinic&#xD;
      2x/weekly or more. The efficacy of the treatment procedure will be evaluated on the basis of&#xD;
      a 2 week observation period.&#xD;
&#xD;
      Treatment efficacy assessment:&#xD;
&#xD;
        -  Assessment of clinical signs and symptoms at entry to the study and after one and two&#xD;
           weeks.&#xD;
&#xD;
        -  Quantitative and qualitative microbiological analysis at entry to the study and after&#xD;
           two weeks.&#xD;
&#xD;
        -  Wound planimetry using PictZar® CDM at entry to the study and after two weeks.&#xD;
&#xD;
      Primary aim:&#xD;
&#xD;
        -  clinical signs assessed by:&#xD;
&#xD;
             1. reduction of slough and necrotic tissue&#xD;
&#xD;
             2. control of exudate&#xD;
&#xD;
             3. presence of granulation tissue&#xD;
&#xD;
        -  reduction of inflammatory signs (surrounding skin)&#xD;
&#xD;
        -  reduction in wound size (assessed by wound planimetry)&#xD;
&#xD;
        -  reduction of bacterial load (quantitative and qualitative microbiological&#xD;
&#xD;
      Secondary aim:&#xD;
&#xD;
      - tolerance and safety assessment:&#xD;
&#xD;
        1. adverse drug reaction&#xD;
&#xD;
        2. adverse events&#xD;
&#xD;
        3. early withdrawal from the study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction of bacterial burden (quantitative bacteriology) Reduction in slough and necrotic tissue (clinical score) Amount and quality of granulation tissue (clinical score) Exudate type and amount (clinical score)</measure>
    <time_frame>weekly</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse device effect (s) Adverse events</measure>
    <time_frame>volunteered at any time or during weekly evaluation visits</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Wound Care</condition>
  <condition>Venous Ulcer Care</condition>
  <condition>Wound Cleansing</condition>
  <condition>Chronic Wound Care</condition>
  <arm_group>
    <arm_group_label>Prontosan wound irrigation solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prontosan® Wound Irrigation Solution (experimental group):&#xD;
cleansing the wound bed at dressing change with Prontosan® Wound Irrigation Solution; a sterile gauze dressing impregnated with the Prontosan® solution will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;&#xD;
placing the primary dressing (Profore® WCL): the dressing will be impregnated with Prontosan® Wound Irrigation Solution;&#xD;
fixing the dressing to the wound using multilayered elastic compression bandaging (Profore®bandaging system).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline irrigation (standard care control)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline (control group):&#xD;
cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;&#xD;
placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;&#xD;
fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prontosan wound irrigation solution</intervention_name>
    <description>Prontosan® Wound Irrigation Solution (experimental group):&#xD;
• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound&#xD;
Saline (control group):&#xD;
cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;&#xD;
placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;&#xD;
fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system).</description>
    <arm_group_label>Prontosan wound irrigation solution</arm_group_label>
    <arm_group_label>Saline irrigation (standard care control)</arm_group_label>
    <other_name>Wound irrigation solution containing PHMB</other_name>
    <other_name>Polihexanide</other_name>
    <other_name>Betaine</other_name>
    <other_name>Wound cleanser</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  males and females aged at least 18 with wounds of venous aetiology (documented by&#xD;
             targeted exams) located in the lower limbs&#xD;
&#xD;
          -  Ankle Brachial Index (ABI) ≥ 0.7&#xD;
&#xD;
          -  patients who have not had an antimicrobial (systemic antibiotic or topical antiseptic)&#xD;
             over the 30 days before joining the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  age below 18 years&#xD;
&#xD;
          -  presence of clinical infection, or current use of antiseptics or antibiotics&#xD;
&#xD;
          -  chronic wounds of long duration (&gt;30cm2 and &gt;1 year duration)&#xD;
&#xD;
          -  involvement in other wound related trials within the past 30 days&#xD;
&#xD;
          -  sensitivity to any of the components of Prontosan® or dressing material&#xD;
&#xD;
          -  intolerance to compression therapy&#xD;
&#xD;
          -  active osteomyelitis in the ulceration area&#xD;
&#xD;
          -  active rheumatoid arthritis (RA) requiring any immunosuppressive therapy&#xD;
&#xD;
          -  collagen vascular disease active treated with steroids&#xD;
&#xD;
          -  chronic diseases that could impact the course of the study (malicious cancer, TB,&#xD;
             AIDS, mental illnesses)&#xD;
&#xD;
          -  plasma protein below 4 g/dl&#xD;
&#xD;
          -  anaemia: haemoglobin below 10 g/dl&#xD;
&#xD;
          -  both, controlled and uncontrolled diabetics (type 1 or 2)&#xD;
&#xD;
          -  patients on any rheological agents (not including aspirin)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar M Alvarez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Calvary Hospital, Wound Care</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Wendelken, RN, DPM</last_name>
    <role>Study Director</role>
    <affiliation>Calvary Hospital, Wound Care</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Calvary hospital center for curative and palliative wound care</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <study_first_submitted>January 12, 2010</study_first_submitted>
  <study_first_submitted_qc>January 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 13, 2010</study_first_posted>
  <last_update_submitted>August 16, 2010</last_update_submitted>
  <last_update_submitted_qc>August 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Ali Koca, MD</name_title>
    <organization>B. Braun Medical Inc</organization>
  </responsible_party>
  <keyword>prontosan</keyword>
  <keyword>wound cleansing</keyword>
  <keyword>wound irrigation</keyword>
  <keyword>phmb</keyword>
  <keyword>polihexanide</keyword>
  <keyword>betaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Varicose Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polihexanide</mesh_term>
    <mesh_term>Betaine</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>August 23, 2011</submitted>
    <returned>September 27, 2011</returned>
    <submitted>February 12, 2013</submitted>
    <returned>March 13, 2013</returned>
    <submitted>July 22, 2014</submitted>
    <returned>August 12, 2014</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

